Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era.

ABSTRACT:

Background

Although the Omicron variant has been reported to reduce COVID-19 severity in the general population, its impact on patients with hematologic malignancies remains uncertain, and epidemiological investigation is warranted.

Methods

We conducted a multicenter retrospective cohort study of 1, 023 patients with hematologic diseases diagnosed with COVID-19 at 22 centers in Japan between January 2020 and January 2023. Outcomes within 60 days after diagnosis including severe and/or prolonged disease, COVID-19-related mortality, and overall survival (OS) were compared between the pre-Omicron and Omicron periods. Multivariable analysis was performed to identify independent adverse prognostic factors.

Results

Severe and/or prolonged disease occurred in 27.5% of patien

SUBMITTER: Okamoto A 

PROVIDER: S-EPMC12626787 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature